Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2006-06-06
2006-06-06
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S188100, C424S194100, C424S196110, C424S208100, C530S330000, C530S324000, C530S350000
Reexamination Certificate
active
07056519
ABSTRACT:
The present invention relates to a method for inducing antibodies neutralizing HIV primary isolates in a mammal, comprising administration of a pharmaceutical composition comprising a polypeptide represented by the formula N-L-C, in which:N represents the amino acid sequence 25–81 of gp41,C represents the amino acid sequence 112–157 of gp41, andL represents a flexible linking sequence comprising from 2 to 30 amino acids.
REFERENCES:
patent: WO 00 08167 (2000-02-01), None
patent: WO 00 40616 (2000-07-01), None
patent: WO 01 44286 (2001-06-01), None
patent: WO 01 70262 (2001-09-01), None
Ho et al. “Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.” Journal of Virology, vol. 61, No. 6 (Jun. 1987), pp. 2024-2028.
Earl et al. “Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140”, Journal of virolgoy, vol. 75, No. 2 (Jan. 2001), pp. 645-653.
Cleveland et al. “Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response”, Virology, vol. 266, No. 1, (Jan. 5, 2000) pp. 66-78.
Weng, Yongkai and Weiss, Carol D., “Mutational Analysis of Residues in the Coiled-Coil Domain of Human Immunofeficiency Virus Type 1 Transmembrane Protein gp41,” Journal of Virology, Dec. 1998, pp. 9676-9682.
Cao, et al., “Effects of Amino Acid Changes in the Extracellular Domain of the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein,” Journal of Virology, May 1993, pp. 2747-2755.
Weng, et al., “Structure-Function Studies of the Self-Assembly Domain of the Human Immunodificiency Virus Type 1 Transmembrane Protein gp41,” Journal of Virology, Jun. 2000, pp. 5368-5372.
LaCasse, et al., “Fusion-Competent Vaccines: Broad Neutralization of Primary Isolates of HIV,” Research Articles, Jan. 15, 1999 vol. 383.
Weissenhorn, et al., “Atomic Structure of the Ectodomain from HIV-1 gp41,” Nature, vol. 387, May 1997.
Malashkevich, et al., “Crystal Structure of the Simian Immunodeficiency Virus (SIV) gp41 core: Conserved Helical Interactions Underlie the Broad Inhibitory Activity of gp41 Peptides,” Proc. Natl. Acad. Sci. USA vol. 95, pp. 9134-9139, Aug. 1998 Biochemistry.
Montefiori, David C. and Evans, Thomas G., “Toward an HIV Type 1 Vaccine that Generates Potent, Broadly Cross-Reactive Neutralizing Antibodies,” Aids Research and Human Retroviruses, vol. 15, No. 8, 1999, pp. 689-698.
Shu, et al., “Helical Interactions in the HIV-1 gp41 Core Reveal Structural Basis for the Inhibitory Activity of gp41 Peptides,” Biochemistry 2000, 39, 1634-1642.
Louis, et al., “Design and Properties of Nccg-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity,” vol. 276, No. 31, Issue of Aug. 3, pp. 29485-29489, 2001.
Wingfield, et al., “The extracellular Domain of Immunodeficiency Virus gp41 Protein: Expression inEscherichia coli, Purification, and Crystallization,” Protein Science (1997), 6:1653-1660, Cambridge University Press.
DeRosny, et al., “Petptides Corresponding to the Heptad Repeat Motifs in the Transmemebrane Protein (gp41) of Human Immunodeficiency Virus Type 1 Elicit Antibodies of Receptor-Activated Conformations of the Envelope Glycoprotein,” Journal of Virology, Sep. 2001, pp. 8859-8863.
Yang, et al., “The Crystal Structure of the SIV gp41 Ectodomain at 1.47 A Resolution,” Journal of Structural Biology, 126, 131-144 (1999).
Caffrey, et al., “Three-Dimensional Solution Structure of the 44 kDa Ectodomain of SIV gp41,” The EMBO Journal vol. 17, No. 16, pp. 4572-4584, 1998.
Boudet Florence
Chevalier Michel
El Habib Raphaëlle
Krell Tino
Sodoyer Regis
Aventis Pasteur S.A.
Hulbert & Berghoff LLP
McDonnell Boehnen
Stucker Jeffrey
LandOfFree
Methods for inducing HIV-neutralizing antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inducing HIV-neutralizing antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inducing HIV-neutralizing antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3620817